Monthly Archives: September 2014

Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells

Posted: September 16, 2014 at 11:45 am

PUBLIC RELEASE DATE:

16-Sep-2014

Contact: Dov Smith dovs@savion.huji.ac.il 972-258-82844 The Hebrew University of Jerusalem @HebrewU

Researchers at the Hebrew University of Jerusalem have developed a new cocktail that is highly effective at coaxing adult cells to become quality pluripotent stem cells.

Regenerative medicine is a new and expanding area that aims to replace lost or damaged cells, tissues or organs through cellular transplantation. Because stem cells derived from human embryos can trigger ethical concerns, a good solution is reprogramming adult cells back to an embryo-like state using a combination of reprogramming factors.

The resulting cells, called induced pluripotent stem cells (iPSCs), could be used to replace those lost to damage or disease. However, scientists have discovered that the process of reprogramming adult cells can introduce genetic abnormalities that limit the cells' usefulness in research and medicine.

To make iPSCs, scientists expose adult cells to a cocktail of genes that are active in embryonic stem cells. iPSCs can then be coaxed to differentiate into other cell types such as nerve or muscle. However, the standard combination of factors used to reprogram cells leads to a high percentage of serious genomic aberrations in the resulting cells. (The reprogramming factors are Oct4, Sox2, Klf4, and Myc known collectively as OSKM).

Now researchers at the Hebrew University of Jerusalem have developed a new cocktail of reprogramming factors that produce high-quality iPSCs. Dr. Yosef Buganim, at the Institute for Medical Research Israel-Canada in the Hebrew University's Faculty of Medicine, worked with scientists at the lab of Whitehead Institute founding member Rudolf Jaenisch, a professor of biology at MIT.

The researchers reasoned that changing the reprogramming factors could reprogram the adult cells in a more controlled way and yield high-quality iPSCs. Working with mouse cells, Dr. Buganim and research scientist Styliani Markoulaki used bioinformatic analysis to design a new cocktail of reprogramming factors (Sall4, Nanog, Esrrb, and Lin28, known collectively as SNEL).

Their results showed that the interaction between reprogramming factors plays a crucial role in determining the quantity and quality of resulting iPSCs and that a different combination of reprogramming factors can in fact produce a much higher quality product.

Continued here:
Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells

Posted in Regenerative Medicine | Comments Off

Laminine Testimonial-kidney failure – Video

Posted: September 16, 2014 at 11:40 am

Laminine Testimonial-kidney failure
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a...

By: Karl Angelo Alipin

Continue reading here:
Laminine Testimonial-kidney failure - Video

Posted in Stem Cell Therapy | Comments Off

Global And China Stem Cell Industry Size 2014 Market Analysis, Growth, Trends and Forecast 2017: MarketResearchReports …

Posted: September 16, 2014 at 11:40 am

Albany, NY (PRWEB) September 15, 2014

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..

View Full Report at http://www.marketresearchreports.biz/analysis/223134

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

Browse All Published Reports by Same Publisher at http://www.marketresearchreports.biz/publisher/67

Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOSTs adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.

TiGenix: TiGenix to participate or present at key conferences in the second half of 2014

Posted: September 16, 2014 at 12:51 am

SEPTEMBER 15, 2014

TiGenix to participate or present at key conferences in the second half of 2014

Leuven (BELGIUM) - September 15, 2014 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the list of conferences in which it will participate during the second half of 2014.

15-16 September Stem Cells & Regenerative Medicine Congress 2014, Boston, USA Participant: Claudia Jimenez, Senior Director Business Development

17 September Regener8, Leeds, UK Presenter: Wilfried Dalemans, Chief Technical Officer

30 September-1 October 14th Biotech in Europe Forum for Global Partnering and Investing, Basel, Switzerland Participant: Claudia Jimenez, Senior Director Business Development

2-3 October 14th Large & Midcap Event, Paris, France Participant: Claudia D'Augusta, Chief Financial Officer

6-8 October Stem Cell Meeting on the Mesa, California, USA Presenter: Eduardo Bravo, Chief Executive Officer

18-22 October 22nd United European Gastroenterology Week (UEGW), Vienna, Austria Participant: Mary Carmen Diez, VP Medical Affairs and New Product Commercialisation

3-5 November BIO-Europe 2014, Frankfurt, Germany Participant: Claudia Jimenez, Senior Director Business Development

Posted in New York Stem Cells | Comments Off

USC researchers discover the healing power of 'rib-tickling'

Posted: September 16, 2014 at 12:47 am

PUBLIC RELEASE DATE:

12-Sep-2014

Contact: Cristy Lytal lytal@med.usc.edu 323-442-2172 University of Southern California - Health Sciences

Unlike salamanders, mammals can't regenerate lost limbs, but they can repair large sections of their ribs.

In a new study in the Journal of Bone and Mineral Research, a team directed by USC Stem Cell researcher Francesca Mariani takes a closer look at rib regeneration in both humans and mice.

The first author of the paper, USC medical student Marissa K. Srour, was a USC undergraduate when she started the project, which earned a 2011 USC Discovery Scholar Prize. Each year, 10 graduating seniors win these coveted prizes, which recognize exceptional new scholarship.

Using CT imaging, Srour, Mariani and their colleague Janice Lee from the University of California, San Francisco, monitored the healing of a human rib that had been partially removed by a surgeon. The eight centimeters of missing bone and one centimeter of missing cartilage did partially repair after six months.

To better understand this repair process, they surgically removed sections of rib cartilage ranging from three to five millimeters from a related mammal, mice. When they removed both rib cartilage and its surrounding sheath of tissue called the "perichondrium," the missing sections failed to repair even after nine months. However, when they removed rib cartilage but left its perichondrium, the missing sections entirely repaired within one to two months.

They also found that a perichondrium retains the ability to produce cartilage even when disconnected from the rib and displaced into nearby muscle tissue further suggesting that the perichondrium contains progenitor or stem cells.

"We believe that the development of this model in the mouse is important for making progress in the field of skeletal repair, where an acute clinical need is present for ameliorating skeletal injury, chronic osteoarthritis and the severe problems associated with reconstructive surgery," said Mariani, assistant professor of Cell and Neurobiology and principal investigator in the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. "At the early stages in our understanding, the mouse provides us with an exceptional ability to make progress, and we are excited about the potential for using cells derived from the rib perichondrium or using rib perichondrium-like cells for regenerative therapy."

More:
USC researchers discover the healing power of 'rib-tickling'

Posted in California Stem Cells | Comments Off

Washington (Stem Cell) – what-when-how

Posted: September 16, 2014 at 12:46 am

WASHINGTON IS ONE of the states of the United States and is located in the northwestern corner of the continental part of the country. Named after President George Washington (1732-99; president, 1789-97), the state of Washington is bordered by Idaho to the east and Oregon to the south. To the west is the Pacific Ocean and to the north the Canadian state of British Columbia. The coastal location and the presence of excellent harbor facilities have meant that maritime trade with Canada and with Pacific Rim countries has been a major part of the states economy.

The eastern portions of the state have less rain and are mainly given over to agriculture, whereas industrial activities are mainly located in the western area, where most of the large urban centers are to be found; these cities house the bulk of the states population. Cities are mostly placed alongside Puget Sound, which is a deep inroad of the Pacific Ocean into the state.

The state has a territory in excess of 71,000 square miles and a population of nearly six million. The state capital is Olympia, but Seattle is a much larger city and is the modern economic center of the state. Located on Puget Sound, Seattle is the home of high-tech companies such as Microsoft and Amazon.com, as well as a cluster of leading biomedical organizations including ZymoGenetics, HeartStream, and Heart Technologies. The CellCyte Genetics Corporation, one of the leading stem cell research companies in the country, recently received a U.S. patent for its new procedure to deliver stem cells in the appropriate form to designated organs in the body. Seattle is also the home of the Starbucks coffee chain, which is one of the targets of antiglobalization protestors. This modern affluence is a contrast to certain periods in the past, when the poverty of Skid Row followed the earlier gold rush period and the ending of the Oregon Trail.

The confluence of so many leading scientifically based companies, together with a variety of educational institutes, has contributed to making Seattle, and indeed the state of Washington, among the most literate or well-educated parts of the United States, according to various measurements. This is reflected in the politics of the state, where Democrats are generally elected with substantial majorities because of votes they receive from the populous western region, which outnumber the right-wing sentiments of the less well-developed eastern region.

Washington is the first state in the country to have women filling all of its leading political positions at the same time, which are the governor and both senators. However, elections are not a procession, and both major parties are represented in public office. The painfully narrow and contested election of Governor Chris Gregoire is one example of the close races that do exist.

At the University of Washington, the Institute for Stem Cell and Regenerative Medicine (ISCRM) is a center for research in stem cell technologies. The Institute was founded in 2006 and now has more than 70 faculty members engaged in relevant research. The ISCRM has a mission to be committed to the ethical pursuit of basic research to unleash the enormous potential of stem cells and thereby develop therapies and cures.

The university is affiliated with the Fred Hutchinson Cancer Research Center and Childrens Hospital and through the integrative work of the ISCRM aims to produce innovative treatments for a range of different health conditions, including heart disease, cancers, and neurodegenerative diseases. The states approach to stem cell research is quite liberal, but federal regulations nevertheless affect the ability of researchers to pursue their work. Existing and legally harvested lines of cells can become degraded with excessive experimentation, and new techniques are required to produce the types of cells required within the various regulatory frameworks.

Read the original post:
Washington (Stem Cell) - what-when-how

Posted in Washington Stem Cells | Comments Off

Laminine Testimonials stroke – Video

Posted: September 16, 2014 at 12:40 am

Laminine Testimonials stroke
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a...

By: Karl Angelo Alipin

Link:
Laminine Testimonials stroke - Video

Posted in Stem Cell Therapy | Comments Off

Stem Cell Testimonials Intro – Video

Posted: September 15, 2014 at 4:49 pm

Stem Cell Testimonials Intro
A quick glimpse at what some of our patients experience with Beike #39;s adult stem cells at our partner treatment center Better Being Hospital! http://www.stemcelltreatmentnow.com http://www.betterbeingthailand.com.

By: Beike Biotech

Link:
Stem Cell Testimonials Intro - Video

Posted in Stem Cell Videos | Comments Off

Next-Generation Stem Cells Transplanted in Human for the First Time

Posted: September 15, 2014 at 1:45 am

Surgeons implanted retinal tissue created after reverting the patient's own cells to a "pluripotent" state

Researchers were able to grow sheets of retinal tissue from induced pluripotent stem cells, and have now implanted them for the first time in a patient. Credit: RIKEN/Foundation for Biomedical Research and Innovation

A Japanese woman in her 70s is the world's first recipient of cells derived from induced pluripotent stem cells, a technology that has created great expectations since it could offer the same advantages as embryo-derived cells but without some of the controversial aspects and safety concerns.

In a two-hour procedure starting at 14:20 local time today, a team of three eye specialists lead by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, transplanted a 1.3 by 3.0 millimeter sheet of retinal pigment epithelium cells into an eye of the Hyogo prefecture resident, who suffers from age-related macular degeneration.

The procedure took place at the Institute of Biomedical Research and Innovation Hospital, next to the RIKEN Center for Developmental Biology (CDB) where ophthalmologist Masayo Takahashi had developed and tested the epithelium sheets. She derived them from the patient's skin cells, after producing induced pluripotent stem (iPS) cells and then getting them to differentiate into retinal cells.

Afterwards, the patient experienced no effusive bleeding or other serious problems, RIKEN has reported.

The patient took on all the risk that go with the treatment as well as the surgery, Kurimoto said in a statement released by RIKEN. I have deep respect for bravery she showed in resolving to go through with it.

He hit a somber note in thankingYoshiki Sasai, a CDB researcher who recenty committed suicide. This project could not have existed without the late Yoshiki Sasais research, which led the way to differentiating retinal tissue from stem cells.

Kurimoto also thanked Shinya Yamanaka, a stem-cell scientist at Kyoto University without whose discovery of iPS cells, this clinical research would not be possible. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for that work.

Kurimoto performed the procedure a mere four days after a health-ministry committee gave Takahashi clearance for the human trials (see 'Next-generation stem cells cleared for human trial').

Continued here:
Next-Generation Stem Cells Transplanted in Human for the First Time

Posted in Stem Cells | Comments Off

Faster way found to create insulin-producing cells

Posted: September 15, 2014 at 1:45 am

University of British Columbia, in collaboration with BetaLogics Venture, a division of Janssen Research & Development, LLC, has published a study highlighting a protocol to convert stem cells into insulin-producing cells. The new procedure could be an important step in the fight against Type 1 diabetes.

The protocol can turn stem cells into reliable, insulin-producing cells in about six weeks, far quicker than the four months it took using previous methods.

"We are a step closer to having an unlimited supply of insulin-producing cells to treat patents with Type 1 diabetes," says Timothy Kieffer who led the research and is a professor in UBC's Department of Cellular and Physiological Sciences and the Department of Surgery.

The protocol transforms stem cells into insulin-secreting pancreatic cells via a cell-culture method. The conversion is completed after the cells are transplanted into a host.

"We have not yet made fully functional cells in a dish, but we are very close," says Kieffer. "The cells we make in the lab produce insulin, but are still immature and need the transplant host to complete the transformation into fully functioning cells."

An important next step for UBC researchers and their industry collaborators is to determine how to prevent the insulin-producing cells' from being rejected by the body.

The research was published Sept. 11, in the journal Nature Biotechnology.

Story Source:

The above story is based on materials provided by University of British Columbia. Note: Materials may be edited for content and length.